

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an offer or an invitation to acquire, purchase or subscribe for securities. This announcement is not a prospectus, Potential investors should read the prospectus dated 2 December 2015 (the “**Prospectus**”) issued by Chuangmei Pharmaceutical Co., Ltd.* 創美藥業股份有限公司 (the “**Company**”) for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered. Unless defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the Prospectus.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States, and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offer of securities in the United States.*

*In connection with the Global Offering, Guotai Junan Securities (Hong Kong) Limited, as stabilising manager (the “**Stabilising Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may over-allocate H Shares or effect any other transactions with a view to stabilising or maintaining the market price of the H Shares at a level higher than that which might otherwise prevail in the open market for a limited period beginning on the Listing Date and expected to end on the 30th day after the last day for lodging of applications under the Hong Kong Public Offering. However, there is no obligation on the Stabilising Manager, its affiliates or any person acting for it to conduct any such stabilising action, which, if commenced, will be done at the sole and absolute discretion of the Stabilising Manager and may be discontinued at any time. Such stabilisation action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilising) Rules, as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Such stabilisation action, if commenced, will be conducted at the absolute discretion of the Stabilising Manager, its affiliates or any person acting for it and may be discontinued at any time, and is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. The details of the intended stabilisation and how it will be regulated under the Securities and Futures Ordinance are set forth in the section headed “Structure of the Global Offering” of the Prospectus.*

Potential investors should be aware that stabilising action cannot be taken to support the price of the H Shares for longer than the stabilisation period which will begin on the Listing Date and is expected to expire on the 30th day after the last day for lodging applications under the Hong Kong Public Offering. After this date, no further stabilising action may be taken, and demand for the H Shares and the price of the H Shares could fall.



創美·CH'MEI

CHUANGMEI PHARMACEUTICAL CO., LTD.*

創美藥業股份有限公司

(a joint stock limited liability company established in the People's Republic of China)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	:	28,000,000 H Shares (subject to the Over-allotment Option)
Number of International Offer Shares	:	25,200,000 H Shares (subject to adjustment and the Over-allotment Option)
Number of Hong Kong Offer Shares	:	2,800,000 H Shares (subject to adjustment)
Maximum Offer Price	:	HK\$8.60 per H Share plus brokerage fee of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)
Nominal value	:	RMB1.00 per H Share
Stock code	:	2289

Sole Sponsor



國泰君安國際
GUOTAI JUNAN INTERNATIONAL

Guotai Junan Capital Limited

Sole Global Coordinator, Sole Bookrunner and Sole Lead Manager



國泰君安國際
GUOTAI JUNAN INTERNATIONAL

Guotai Junan Securities (Hong Kong) Limited

Application has been made by the Company to the Listing Committee of the Stock Exchange for the granting of the approval for the listing of, and permission to deal in, the H Shares to be issued pursuant to the Global Offering as described in the Prospectus (including the additional H Shares which may be issued upon the exercise of the Over-allotment Option).

* For identification purposes only

Assuming the Global Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Monday, 14 December 2015, it is expected that dealings in the H Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Monday, 14 December 2015. In the event the Over-allotment Option is exercised, an announcement will be made by the Company on our Company's website at www.chmyy.com and the website of the Stock Exchange at www.hkexnews.hk.

The Global Offering comprises the Hong Kong Public Offering of initially 2,800,000 H Shares (subject to adjustment), representing 10% of the initial number of Offer Shares, and the International Offering of initially 25,200,000 H Shares (subject to adjustment and the Over-allotment Option), representing 90% of the initial number of Offer Shares. The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to adjustment as described in the section headed "Structure of the Global Offering" in the Prospectus.

In connection with the Global Offering, our Company is expected to grant to the International Underwriters (exercisable by the Sole Global Coordinator on behalf of the International Underwriters) the Over-allotment Option. Pursuant to the Over-allotment Option, the Sole Global Coordinator will have the right to require the Company to issue and allot up to an aggregate of 4,200,000 H Shares representing in aggregate 15% of the initial number of the Offer Shares at the Offer Price to cover, among other things, over-allocations in the International Offering, if any, subject to the same terms and conditions as the other Offer Shares.

Subject to the granting of the approval for listing of, and permission to deal in, the H Shares on the Stock Exchange and the Company's compliance with the stock admission requirements of HKSCC, the H Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the H Shares on the Stock Exchange or any other date as determined by HKSCC. Settlement of transactions between participants of the Stock Exchange is required to take place in CCASS on the second business day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made for the H Shares to be admitted into CCASS.

The Offer Price will not be more than HK\$8.60 per Offer Share and is currently expected to be not less than HK\$7.60 per Offer Share. Applicants for Hong Kong Offer Shares are required to pay, on application, the Offer Price of HK\$8.60 for each Hong Kong Offer Share together with a brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%, subject to refund if the Offer Price as finally determined is less than HK\$8.60 per Offer Share.

Applications for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions of the Prospectus and the related Application Forms and the designated website (www.eipo.com.hk) in relation to the White Form eIPO.

Applicants who would like to be allocated the Hong Kong Offer Shares in their own names should (i) complete and sign the **WHITE** Application Forms; or (ii) submit applications online through the designated website of the **White Form eIPO** Service Provider at www.eipo.com.hk under the **White Form eIPO** service. Applicants who would like to have the allocated Hong Kong Offer Shares issued in the name of HKSCC Nominees and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants should (i) complete and sign the **YELLOW** Application Forms; or (ii) give **electronic application instructions** to HKSCC via CCASS.

Copies of the Prospectus, together with the **WHITE** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Wednesday, 2 December 2015 until 12:00 noon on Monday, 7 December 2015 from:

1. any of the following offices of the Hong Kong Underwriters:

Guotai Junan Securities (Hong Kong) Limited

27th Floor, Low Block
Grand Millennium Plaza
181 Queen's Road Central
Hong Kong

Ever-Long Securities Company Limited

18th Floor, Dah Sing Life Building
99-105 Des Voeux Road Central
Hong Kong

Luk Fook Securities (HK) Limited

Units 502-6, 5/F, Low Block
Grand Millennium Plaza
181 Queen's Road Central
Hong Kong

2. any of the following branches of **Industrial and Commercial Bank of China (Asia) Limited**:

District	Branch Name	Address
Hong Kong Island	West Point Branch	242-244 Queen's Road West, Sai Ying Pun
	Queen's Road Central Branch	122-126 Queen's Road Central, Central
	Causeway Bay Branch	Shop A on G/F, 1/F, Hennessy Apartments, 488 & 490 Hennessy Road
Kowloon	Tsim Sha Tsui Branch	Shop 1&2, G/F, No. 35-37 Hankow Road, Tsim Sha Tsui
	Mei Foo Branch	Shop N95A, 1/F, Mount Sterling Mall, Mei Foo Sun Chuen
	Prince Edward Branch	777 Nathan Road, Mongkok
	Ngau Tau Kok Branch	Shop Nos. G211-214, G/F, Phase II, Amoy Plaza, 77 Ngau Tau Kok Road

New Territories	Tsuen Wan Castle Peak Road Branch	G/F, 423-427 Castle Peak Road, Tsuen Wan
	Kwai Fong Branch	C63A-C66, 2/F, Kwai Chung Plaza, Kwai Fong
	Tuen Mun Branch	217 A-F Central Services Building, Nan Fung Industrial City, 18 Tin Hau Road, Tuen Mun
	Tai Po Branch	Shop F, G/F, Mee Fat Building, No 34-38 Tai Wing Lane, Tai Po
	Shatin Branch	Shop 22J, Level 3, Shatin Centre

Copies of the Prospectus, together with the **YELLOW** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Wednesday, 2 December 2015 until 12:00 noon on Monday, 7 December 2015 from:

- (1) the Depository Counter of HKSCC at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong; or
- (2) your stockbroker.

The **WHITE** or **YELLOW** Application Form completed in accordance with the instructions printed thereon, together with a cheque or banker's cashier order payable to "ICBC (Asia) Nominee Limited – Chuangmei Pharmaceutical Public Offer" attached should be deposited in the special collection boxes provided at any of the branches of Industrial and Commercial Bank of China (Asia) Limited referred to above on such dates and during such time as specified in the Prospectus and Application Forms.

Applicants applying by **White Form eIPO** may submit applications to the **White Form eIPO** Service Provider through the designated website at www.eipo.com.hk from 9:00 a.m. on Wednesday, 2 December 2015 until 11:30 a.m. on Monday, 7 December 2015 or such later time as described in the section headed "How to Apply for Hong Kong Offer Shares – 10. Effect of Bad Weather on the Opening of the Application Lists" in the Prospectus (24 hours daily, except on the last application day).

CCASS Clearing/Custodian Participants can input **electronic application instructions** at the following times on the following dates:

Wednesday, 2 December 2015	— 9:00 a.m. to 8:30 p.m.⁽¹⁾
Thursday, 3 December 2015	— 8:00 a.m. to 8:30 p.m.⁽¹⁾
Friday, 4 December 2015	— 8:00 a.m. to 8:30 p.m.⁽¹⁾
Saturday, 5 December 2015	— 8:00 a.m. to 1:00 p.m.⁽¹⁾
Monday, 7 December 2015	— 8:00 a.m.⁽¹⁾ to 12:00 noon

Note:

- (1) These times are subject to change as HKSCC may determine from time to time with prior notification to CCASS Clearing/Custodian Participants.

CCASS Investor Participants can input **electronic application instructions** from 9:00 a.m. on Wednesday, 2 December 2015 until 12:00 noon on Monday, 7 December 2015 or such later time as described in the section headed “How to Apply for Hong Kong Offer Shares – 10. Effect of bad weather on the opening of the applications lists” in the Prospectus. The application lists will be open from 11:45 a.m. to 12:00 noon on Monday, 7 December 2015, the last application day or such later time as described in the section headed “How to Apply for Hong Kong Offer Shares – 10. Effect of Bad Weather on the Opening of the Application Lists” in the Prospectus.

Please refer to the sections headed “Structure of the Global Offering” and “How to Apply for Hong Kong Offer Shares” in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

The Company expects to announce the final Offer Price, the level of indication of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on Friday, 11 December 2015 in the South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese), and on the Company’s website at www.chmyy.com and the website of the Stock Exchange at www.hkexnews.hk. Results of allocations in the Hong Kong Public Offering (with successful applicants’ identification document numbers, where applicable) will be available through a variety of channels from Friday, 11 December 2015 as described in the section headed “How to Apply for Hong Kong Offer Shares – 11. Publication of Results” in the Prospectus including in the South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese), on our Company’s website at www.chmyy.com and the website of the Stock Exchange at www.hkexnews.hk.

No temporary documents of title will be issued in respect of the Offer Shares. No receipt will be issued for sums paid on application. Share certificates will only become valid documents of title at 8:00 a.m. on Monday, 14 December 2015 provided that the Global Offering has become unconditional in all respects and neither the Underwriting Agreements has been terminated in accordance with its terms.

Dealing in the H Shares on the Stock Exchange is expected to commence at 9:00 a.m. on Monday, 14 December 2015. The H Shares will be traded in board lots of 500 each. The stock code of the Company is 2289.

By order of the Board
Chuangmei Pharmaceutical Co., Ltd.
Mr. Yao Chuanglong
Chairman

Hong Kong, 2 December 2015

As at the date of this announcement, the executive Directors are Mr. Yao Chuanglong, Ms. Zheng Yuyan, Mr. Fan Jianbo and Mr. Lin Zhixiong; the non-executive Director is Ms. You Zeyan; and the independent non-executive Directors are Mr. Wan Chi Wai Anthony, Mr. Zhou Tao and Mr. Guan Jian (also known as Guan Suzhe).